Certara Reports Third Quarter 2022 Financial Results
Certara, Inc. (Nasdaq: CERT) reported significant growth for Q3 2022, achieving $84.7 million in revenue, a 15% increase year-over-year. This growth was complemented by a net income of $3.9 million, a notable turnaround from a net loss of $1.8 million in the same quarter last year. Adjusted EBITDA rose 25% to $32.7 million. The company reiterated its full-year revenue guidance of $325 million to $335 million. Additionally, Arsenal Investment Partners is set to acquire 30 million shares at $15 per share, strengthening shareholder support.
- Revenue increased by 15% year-over-year to $84.7 million.
- Net income improved to $3.9 million from a net loss of $1.8 million.
- Adjusted EBITDA grew 25% to $32.7 million.
- Reiterated full-year revenue guidance of $325 million to $335 million.
- Arsenal Investment Partners to acquire 30 million shares at $15 per share.
- Adjusted net income decreased slightly to $16.6 million from $17.2 million year-over-year.
- Diluted adjusted earnings per share fell to $0.10 from $0.11 in the same quarter last year.
Biosimulation software and services fuel third quarter growth
PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance.
Third Quarter Highlights:
- Revenue was
$84.7 million , compared to$73.9 million in the third quarter of 2021, representing growth of15% over the third quarter of 2021 on a reported basis and18% at constant currency. - Net income was
$3.9 million , compared to net loss of$1.8 million in the third quarter of 2021, an increase of$5.7 million in income over the third quarter of 2021. - Adjusted EBITDA was
$32.7 million , compared to$26.1 million in the third quarter of 2021, representing growth of25% over the third quarter of 2021. - Reiterated full year guidance.
“Certara delivered another strong quarter with continued strength in biosimulation revenue,” said William F. Feehery, chief executive officer. “We are pleased to reiterate our full year guidance for 2022. Overall, we continue to see industry trends moving in the right direction to drive growth in the adoption of biosimulation globally, and I am confident our ability to deliver on our mission to accelerate medicines to patients.”
“We also separately announced today that long-term shareholder Arsenal Investment Partners has signed an agreement to acquire EQT’s remaining 30 million shares in the Company at
Third Quarter 2022 Results
“We finished the third quarter with a healthy balance sheet and operating cash flow growth, which leaves us well positioned to execute our business strategy for the remainder of 2022 and into 2023. We are confident in our ability to execute our 2022 full year guidance,” said Andrew Schemick, chief financial officer.
Total revenue for the third quarter of 2022 was
On a constant currency basis, total revenue for the third quarter of 2022 was
Total cost of revenue for the third quarter of 2022 was
Total operating expenses for the third quarter of 2022 were
Net income for the third quarter of 2022 was
Diluted earnings per share for the third quarter 2022 was
Adjusted EBITDA for the third quarter of 2022 was
Adjusted net income for the third quarter of 2022 was
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||
| Key Financials (in millions, except per share data) | ||||||||||||||
| Revenue | $ | 84.7 | $ | 73.9 | $ | 249.0 | $ | 210.8 | ||||||
| Net income (loss) | $ | 3.9 | $ | (1.8 | ) | $ | 5.6 | $ | (3.6 | ) | ||||
| Diluted earnings per share | $ | 0.02 | $ | (0.01 | ) | $ | 0.03 | $ | (0.02 | ) | ||||
| Adjusted EBITDA | $ | 32.7 | $ | 26.1 | $ | 88.3 | $ | 75.5 | ||||||
| Adjusted net income | $ | 16.6 | $ | 17.2 | $ | 48.2 | $ | 43.4 | ||||||
| Adjusted diluted earnings per share | $ | 0.10 | $ | 0.11 | $ | 0.30 | $ | 0.28 | ||||||
| Cash and cash equivalents | $ | 210.5 | $ | 416.9 | ||||||||||
2022 Financial Outlook
Certara is reiterating its previously reported guidance for full year 2022 guidance of
| FY 2022 Guidance | ||
| In millions, except per share data | ||
| Revenue | $ | 325 - |
| Adjusted EBITDA | $ | 112- |
| Adjusted diluted earnings per share | $ | 0.43 - |
Fully diluted shares for 2022 to be in the range of 159 million to 161 million.
GAAP tax rate for 2022 to be in the range of
Cash tax rate for 2022 to be in the range of
Webcast and Conference Call Details
Certara will host a conference call today, November 7, 2022, at 5:00 p.m. ET to discuss its third quarter 2022 financial results. Investors interested in listening to the conference call are required to register online in advance of the call. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.
Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
Forward-Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company’s future business and financial performance, revenue, margin, and bookings. These statements typically contain words such as “believe,” “may,” “potential,” “will,” “plan,” “could,” “estimate,” “expects” and “anticipates” or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company’s ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession and currency exchange fluctuation; trends in research and development (R&D) spending; delays or cancellations in projects due to supply chain interruptions or disruptions or delays to pipeline development and clinical trials experienced by our customers due to COVID-19 or other external factors, consolidation within the biopharmaceutical industry; reduction in the use of the Company’s products by academic institutions; pricing pressures; the Company’s ability to successfully enter new markets, increase its customer base and expand its relationships with existing customers; the impact of the Pinnacle 21 acquisition and any future acquisitions and our ability to successfully integrate such acquisitions; the occurrence of natural disasters and epidemic diseases, such as the recent COVID-19 pandemic; the occurrence of global conflicts, such as the conflict between Russian and Ukraine; any delays or defects in the release of new or enhanced software or other biosimulation tools; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by its existing customers; our ability to accurately estimate costs associated with its fixed-fee contracts; our ability to retain key personnel or recruit additional qualified personnel; lower utilization rates by our employees as a result of natural disasters and epidemic diseases, such as COVID-19; risks related to our contracts with government customers; our ability to sustain recent growth rates; our ability to successfully operate a global business; our ability to comply with applicable laws and regulations; risks related to litigation; the adequacy of its insurance coverage and ability to obtain adequate insurance coverage in the future; our ability to perform in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; future capital needs; the ability of our bookings to accurately predict future revenue and our ability to realize revenue on backlog; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity; our ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing use of third-party open source software; any breach of its security measures or unauthorized access to customer data; our ability to adequately enforce or defend ownership and use of our intellectual property and other proprietary rights; any allegations of infringement, misappropriation or violations of a third party’s intellectual property rights; our ability to meet obligations under indebtedness and have sufficient capital to operate our business; any limitations on our ability to pursue business strategies due to restrictions under our current or future indebtedness; any impairment of goodwill or other intangible assets; our ability to use our net operating losses and R&D tax credit carryforwards; the accuracy of management’s estimates and judgments relating to critical accounting policies and changes in financial reporting standards or interpretations; any inability to design, implement, and maintain effective internal controls or inability to remediate any internal controls deemed ineffective; the costs and management time associated with operating as a publicly traded company; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the Company with the Securities and Exchange Commission on March 1, 2022, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events. Factors that may materially affect our results and those risks listed in filings with the SEC.
A Note on Non-GAAP Financial Measures
This press release contains “non-GAAP measures” that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the Company makes use of the non-GAAP financial measures adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and constant currency (“CC”) revenue, which are not recognized terms under GAAP. These measures should not be considered as alternatives to net income (loss) or GAAP diluted earnings per share or revenue as measures of financial performance or any other performance measure derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
You should refer to the footnotes below as well as the “Non-GAAP Financial Measures” section in this press release below for a further explanation of these measures and reconciliations of these non-GAAP measures in specific periods to their most directly comparable financial measure calculated and presented in accordance with GAAP for those periods.
Management uses various financial metrics, including total revenues, income (loss) from operations, net income (loss), and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company’s business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.
Management believes that adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and CC revenue are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, each of these measures is frequently used by analysts, investors, and other interested parties to evaluate and assess performance. Furthermore, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We adjust revenues for constant currency to provide a framework for assessing how our business performed excluding the effect of foreign currency rate fluctuations. and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance.
Please note that the Company has not reconciled the adjusted EBITDA or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
(1) CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported in currencies other than U.S. Dollars are converted into USD at the average exchange rates in effect for the comparable prior periods.
(2) Adjusted EBITDA represents net income excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, acquisition and integration expense and other items not indicative of our ongoing operating performance.
(3) Adjusted net income and adjusted diluted earnings per share exclude the effect of equity-based compensation expense, amortization of acquisition-related intangible assets, acquisition and integration expense, and other items not indicative of our ongoing operating performance as well as income tax provision adjustment for such charges.
In evaluating adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.
Contacts:
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com
CERTARA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| THREE MONTHS ENDED | NINE MONTHS ENDED | |||||||||||||||
| SEPTEMBER 30, | SEPTEMBER 30, | |||||||||||||||
| (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenues | $ | 84,700 | $ | 73,944 | $ | 249,011 | $ | 210,758 | ||||||||
| Cost of revenues | 32,812 | 28,769 | 100,795 | 82,327 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 6,376 | 5,082 | 19,608 | 13,423 | ||||||||||||
| Research and development | 6,318 | 4,530 | 21,607 | 13,862 | ||||||||||||
| General and administrative | 17,327 | 26,199 | 53,444 | 60,795 | ||||||||||||
| Intangible asset amortization | 10,591 | 9,592 | 31,095 | 28,527 | ||||||||||||
| Depreciation and amortization expense | 417 | 533 | 1,321 | 1,687 | ||||||||||||
| Total operating expenses | 41,029 | 45,936 | 127,075 | 118,294 | ||||||||||||
| Income (loss) from operations | 10,859 | (761 | ) | 21,141 | 10,137 | |||||||||||
| Other income (expenses): | ||||||||||||||||
| Interest expense | (5,221 | ) | (3,289 | ) | (12,328 | ) | (13,549 | ) | ||||||||
| Other, net | 2,855 | 657 | 6,217 | 194 | ||||||||||||
| Total other expenses | (2,366 | ) | (2,632 | ) | (6,111 | ) | (13,355 | ) | ||||||||
| Income (loss) before income taxes | 8,493 | (3,393 | ) | 15,030 | (3,218 | ) | ||||||||||
| Provision of income taxes | 4,557 | (1,631 | ) | 9,473 | 349 | |||||||||||
| Net Income (loss) | 3,936 | (1,762 | ) | 5,557 | (3,567 | ) | ||||||||||
| Net income (loss) per share attributable to common stockholders: | ||||||||||||||||
| Basic | $ | 0.03 | $ | (0.01 | ) | $ | 0.04 | $ | (0.02 | ) | ||||||
| Diluted | $ | 0.02 | $ | (0.01 | ) | $ | 0.03 | $ | (0.02 | ) | ||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 157,140,166 | 149,016,609 | 156,523,022 | 147,894,227 | ||||||||||||
| Diluted | 159,587,645 | 149,016,609 | 159,392,534 | 147,894,227 | ||||||||||||
CERTARA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| SEPTEMBER 30, | DECEMBER 31, | |||||||
| (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) | 2022 | 2021 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 210,509 | $ | 185,797 | ||||
| Accounts receivable, net of allowance for credit losses of | 74,806 | 69,555 | ||||||
| Restricted cash | 3,274 | 827 | ||||||
| Prepaid expenses and other current assets | 16,503 | 18,548 | ||||||
| Total current assets | 305,092 | 274,727 | ||||||
| Other assets: | ||||||||
| Property and equipment, net | 2,609 | 2,935 | ||||||
| Operating lease right-of-use assets | 11,481 | 12,634 | ||||||
| Goodwill | 696,921 | 703,371 | ||||||
| Intangible assets, net of accumulated amortization of | 481,536 | 511,823 | ||||||
| Deferred income taxes | 4,158 | 4,073 | ||||||
| Other long-term assets | 6,896 | 2,167 | ||||||
| Total assets | $ | 1,508,693 | $ | 1,511,730 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,002 | $ | 7,458 | ||||
| Accrued expenses | 26,552 | 29,830 | ||||||
| Current portion of deferred revenue | 40,434 | 45,496 | ||||||
| Current portion of long-term debt | 3,020 | 3,020 | ||||||
| Current operating lease liabilities | 3,422 | 5,040 | ||||||
| Other current liabilities | 100 | 1,381 | ||||||
| Total current liabilities | 76,530 | 92,225 | ||||||
| Long-term liabilities: | ||||||||
| Deferred revenue, net of current portion | 1,884 | 1,531 | ||||||
| Deferred income taxes | 75,522 | 76,098 | ||||||
| Operating lease liabilities, net of current portion | 8,509 | 8,256 | ||||||
| Long-term debt, net of current portion and debt discount | 290,428 | 291,746 | ||||||
| Other long-term liabilities | 1,422 | 25 | ||||||
| Total liabilities | 454,295 | 469,881 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred shares, | — | — | ||||||
| Common shares, | 1,599 | 1,596 | ||||||
| Additional paid-in capital | 1,143,638 | 1,119,821 | ||||||
| Accumulated deficit | (70,047 | ) | (75,604 | ) | ||||
| Accumulated other comprehensive loss | (17,928 | ) | (3,926 | ) | ||||
| Treasury stock at cost, 104,544 and 1,100 shares at September 30, 2022 and December 31, 2021, respectively | (2,864 | ) | (38 | ) | ||||
| Total stockholders’ equity | 1,054,398 | 1,041,849 | ||||||
| Total liabilities and stockholders’ equity | $ | 1,508,693 | $ | 1,511,730 | ||||
CERTARA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| NINE MONTHS ENDED SEPTEMBER 30 | ||||||||
| (IN THOUSANDS) | 2022 | 2021 | ||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | $ | 5,557 | $ | (3,567 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation and amortization of property and equipment | 1,321 | 1,687 | ||||||
| Amortization of intangible assets | 38,007 | 30,435 | ||||||
| Amortization of debt issuance costs | 1,156 | 1,144 | ||||||
| Provision for credit losses | 468 | 39 | ||||||
| Loss on retirement of assets | 56 | 304 | ||||||
| Equity-based compensation expense | 23,818 | 20,846 | ||||||
| Unrealized loss on interest rate swap | — | 1,750 | ||||||
| Deferred income taxes | (3,209 | ) | 1,796 | |||||
| Changes in assets and liabilities | ||||||||
| Accounts receivable | (7,895 | ) | (6,148 | ) | ||||
| Prepaid expenses and other assets | 4,209 | (5,504 | ) | |||||
| Accounts payable and other liabilities | (3,404 | ) | (1,650 | ) | ||||
| Deferred revenue | (1,727 | ) | (1,575 | ) | ||||
| Other current liabilities | (1,088 | ) | 216 | |||||
| Changes in operating lease assets and liabilities, net | (211 | ) | (216 | ) | ||||
| Net cash provided by operating activities | 57,058 | 39,557 | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures | (1,249 | ) | (995 | ) | ||||
| Capitalized development costs | (8,106 | ) | (5,490 | ) | ||||
| Business acquisitions, net of cash acquired | (5,883 | ) | (14,114 | ) | ||||
| Net cash used in investing activities | (15,238 | ) | (20,599 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Net proceeds from public offering of common stock | — | 133,351 | ||||||
| Proceeds from borrowings on long-term debt | — | 89 | ||||||
| Payment on long term debt and finance lease obligations | (2,483 | ) | (3,147 | ) | ||||
| Payment of debt issuance costs | — | (2,942 | ) | |||||
| Payments on financing component of interest rate swap | (1,085 | ) | (216 | ) | ||||
| Payment of taxes on shares withheld for employee taxes | (2,827 | ) | (100 | ) | ||||
| Net cash used in (provided for) financing activities | (6,395 | ) | 127,035 | |||||
| Effect of foreign exchange rate changes on cash and cash equivalents, and restricted cash | (8,266 | ) | (1,326 | ) | ||||
| Net increase in cash and cash equivalents, and restricted cash | 27,159 | 144,667 | ||||||
| Cash and cash equivalents, and restricted cash, at beginning of period | 186,624 | 273,291 | ||||||
| Cash and cash equivalents, and restricted cash, at end of period | $ | 213,783 | $ | 417,958 | ||||
NON-GAAP FINANCIAL MEASURES
The following table reconciles net income (loss) to adjusted EBITDA:
| THREE MONTHS ENDED SEPTEMBER 30 | NINE MONTHS ENDED SEPTEMBER 30 | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Net income (loss)(a) | $ | 3,936 | $ | (1,762 | ) | $ | 5,557 | $ | (3,567 | ) | ||||||
| Interest expense(a) | 5,221 | 3,289 | 12,328 | 13,549 | ||||||||||||
| Interest income(a) | (322 | ) | (84 | ) | (347 | ) | (255 | ) | ||||||||
| (Benefit from) provision for income taxes(a) | 4,557 | (1,631 | ) | 9,473 | 349 | |||||||||||
| Depreciation and amortization expense(a) | 417 | 533 | 1,321 | 1,687 | ||||||||||||
| Intangible asset amortization(a) | 12,846 | 10,209 | 38,007 | 30,436 | ||||||||||||
| Currency (gain) loss(a) | (2,376 | ) | (545 | ) | (5,639 | ) | (189 | ) | ||||||||
| Equity-based compensation expense(b) | 6,804 | 8,165 | 23,818 | 20,846 | ||||||||||||
| Acquisition-related expenses(d) | 253 | 7,561 | 1,331 | 9,713 | ||||||||||||
| Transaction-related expenses(e) | 596 | 154 | 724 | 1,776 | ||||||||||||
| Severance expense(f) | 722 | — | 722 | — | ||||||||||||
| Loss on disposal of fixed assets(g) | 49 | 22 | 56 | 304 | ||||||||||||
| Executive recruiting expense(h) | — | 86 | — | 413 | ||||||||||||
| First-year Sarbanes-Oxley implementation costs(i) | — | 129 | 961 | 469 | ||||||||||||
| Adjusted EBITDA | $ | 32,703 | $ | 26,126 | $ | 88,312 | $ | 75,531 | ||||||||
The following table reconciles net income (loss) to adjusted net income:
| THREE MONTHS ENDED | NINE MONTHS ENDED | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Net income (loss)(a) | $ | 3,936 | $ | (1,762 | ) | $ | 5,557 | $ | (3,567 | ) | ||||||
| Currency (gain) loss(a) | (2,376 | ) | (545 | ) | (5,639 | ) | (189 | ) | ||||||||
| Equity-based compensation expense(b) | 6,804 | 8,165 | 23,818 | 20,846 | ||||||||||||
| Amortization of acquisition-related intangible assets(c) | 10,921 | 8,569 | 32,900 | 25,473 | ||||||||||||
| Acquisition-related expenses(d) | 253 | 7,561 | 1,331 | 9,713 | ||||||||||||
| Transaction-related expenses(e) | 596 | 154 | 724 | 1,776 | ||||||||||||
| Severance expense(f) | 722 | — | 722 | — | ||||||||||||
| Loss on disposal of fixed assets(g) | 49 | 22 | 56 | 304 | ||||||||||||
| Executive recruiting expense(h) | — | 86 | — | 413 | ||||||||||||
| First-year Sarbanes-Oxley implementation costs(i) | — | 129 | 961 | 469 | ||||||||||||
| Income tax expense impact of adjustments(j) | (4,257 | ) | (5,188 | ) | (12,236 | ) | (11,810 | ) | ||||||||
| Adjusted Net Income | $ | 16,648 | $ | 17,191 | $ | 48,194 | $ | 43,428 | ||||||||
The following table reconciles diluted earnings per share to adjusted diluted earnings per share:
| THREE MONTHS ENDED SEPTEMBER 30 | NINE MONTHS ENDED SEPTEMBER 30 | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands except share and per share data) | ||||||||||||||||
| Diluted earnings per share(a) | $ | 0.02 | $ | (0.01 | ) | $ | 0.03 | $ | (0.02 | ) | ||||||
| Currency gain(a) | (0.01 | ) | — | (0.04 | ) | — | ||||||||||
| Equity-based compensation expense(b) | 0.05 | 0.05 | 0.16 | 0.13 | ||||||||||||
| Amortization of acquisition-related intangible assets(c) | 0.07 | 0.05 | 0.21 | 0.17 | ||||||||||||
| Acquisition-related expenses(d) | — | 0.05 | 0.01 | 0.06 | ||||||||||||
| Transaction-related expenses(e) | — | — | — | 0.02 | ||||||||||||
| Severance expense(f) | — | — | — | — | ||||||||||||
| Loss on disposal of fixed assets(g) | — | — | — | — | ||||||||||||
| Executive recruiting expense(h) | — | — | — | — | ||||||||||||
| First-year Sarbanes-Oxley implementation costs(i) | — | — | 0.01 | — | ||||||||||||
| Income tax expense impact of adjustments(j) | (0.03 | ) | (0.03 | ) | (0.08 | ) | (0.08 | ) | ||||||||
| Adjusted Diluted Earnings Per Share | $ | 0.10 | $ | 0.11 | $ | 0.30 | $ | 0.28 | ||||||||
| Diluted weighted average common shares outstanding | 157,140,166 | 149,016,609 | 156,523,022 | 147,894,227 | ||||||||||||
| Effect of potentially dilutive shares outstanding(k) | 2,447,479 | 4,303,765 | 2,869,512 | 4,584,295 | ||||||||||||
| Diluted weighted average common shares outstanding | 159,587,645 | 153,320,374 | 159,392,534 | 152,478,522 | ||||||||||||
The following tables reconcile revenues to the revenues adjusted for constant currency:
| THREE MONTHS ENDED SEPTEMBER 30, | CHANGE | ||||||||||||||||||||||
| 2022 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||
| Actual | CC | Actual | Actual | Actual | CC Impact | Adjust for CC | |||||||||||||||||
| (GAAP) | (non-GAAP) | (GAAP) | (GAAP) | (GAAP) | (non-GAAP) | (non-GAAP) | |||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Software | $ | 28,392 | $ | 29,694 | $ | 19,268 | $ | 9,124 | 47 | % | $ | 1,302 | 54 | % | |||||||||
| Services | 56,308 | 57,832 | 54,676 | 1,632 | 3 | % | 1,524 | 6 | % | ||||||||||||||
| Total Revenue | $ | 84,700 | $ | 87,526 | $ | 73,944 | $ | 10,756 | 15 | % | $ | 2,826 | 18 | % | |||||||||
| NINE MONTHS ENDED SEPTEMBER 30, | CHANGE | ||||||||||||||||||||||
| 2022 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||
| Actual | CC | Actual | Actual | Actual | CC Impact | Adjust for CC | |||||||||||||||||
| (GAAP) | (non-GAAP) | (GAAP) | (GAAP) | (GAAP) | (non-GAAP) | (non-GAAP) | |||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Software | $ | 86,309 | $ | 89,005 | $ | 61,284 | $ | 25,025 | 41 | % | $ | 2,696 | 45 | % | |||||||||
| Services | 162,702 | 165,687 | 149,474 | 13,228 | 9 | % | 2,985 | 11 | % | ||||||||||||||
| Total Revenue | $ | 249,011 | $ | 254,692 | $ | 210,758 | $ | 38,253 | 18 | % | $ | 5,681 | 21 | % | |||||||||
(a) Represents amounts as determined under GAAP.
(b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.
(c) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.
(d) Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.
(e) Represents costs associated with our public offerings that are not capitalized.
(f) Represents charges for severance provided to former executives and non-executives.
(g) Represents the gain/loss related to disposal of fixed assets.
(h) Represents recruiting and relocation expenses related to hiring senior executives.
(i) Represents the first-year Sarbanes-Oxley costs for accounting and consulting fees related to the Company's preparation to comply with Section 404 of the Sarbanes-Oxley Act in 2021, as well as implementing cost of ASC 842.
(j) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.
(k) Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding.
FAQ
What were Certara's third quarter 2022 earnings results?
How does Certara's Q3 2022 performance compare to Q3 2021?
What is Certara's guidance for full-year 2022?
Who is acquiring shares from Certara and what are the terms?
What are the adjusted earnings per share results for Q3 2022?
